KR20200024145A - L-오르니틴 페닐아세테이트의 제조방법 - Google Patents

L-오르니틴 페닐아세테이트의 제조방법 Download PDF

Info

Publication number
KR20200024145A
KR20200024145A KR1020197036485A KR20197036485A KR20200024145A KR 20200024145 A KR20200024145 A KR 20200024145A KR 1020197036485 A KR1020197036485 A KR 1020197036485A KR 20197036485 A KR20197036485 A KR 20197036485A KR 20200024145 A KR20200024145 A KR 20200024145A
Authority
KR
South Korea
Prior art keywords
ornithine
less
composition
ornithine phenylacetate
phenylacetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197036485A
Other languages
English (en)
Korean (ko)
Inventor
루드윅 필슬
조르그 윈클러
프랭크 드마틴
바실 엘리트진
Original Assignee
오세라 테라퓨틱스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오세라 테라퓨틱스, 아이엔씨. filed Critical 오세라 테라퓨틱스, 아이엔씨.
Publication of KR20200024145A publication Critical patent/KR20200024145A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38Separation; Purification; Stabilisation; Use of additives
    • C07C227/40Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38Separation; Purification; Stabilisation; Use of additives
    • C07C227/40Separation; Purification
    • C07C227/42Crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32Phenylacetic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197036485A 2017-05-11 2018-05-07 L-오르니틴 페닐아세테이트의 제조방법 Ceased KR20200024145A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504911P 2017-05-11 2017-05-11
US62/504,911 2017-05-11
PCT/US2018/031405 WO2018208677A1 (en) 2017-05-11 2018-05-07 Processes of making l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
KR20200024145A true KR20200024145A (ko) 2020-03-06

Family

ID=64104920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036485A Ceased KR20200024145A (ko) 2017-05-11 2018-05-07 L-오르니틴 페닐아세테이트의 제조방법

Country Status (10)

Country Link
US (1) US11066352B2 (https=)
EP (1) EP3621947A4 (https=)
JP (1) JP7126520B2 (https=)
KR (1) KR20200024145A (https=)
CN (1) CN110740988A (https=)
AU (1) AU2018266357B2 (https=)
CA (1) CA3063134A1 (https=)
IL (1) IL270413B (https=)
MX (1) MX389665B (https=)
WO (1) WO2018208677A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
KR102852068B1 (ko) * 2019-05-09 2025-08-28 오세라 테라퓨틱스, 아이엔씨. 간성 뇌증의 평가 및 치료 방법

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (https=) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
DE4020980C1 (https=) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1179347A4 (en) 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd CONTROL SUBSTANCES FOR LIVER FUNCTION
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
ATE441409T1 (de) 2001-03-15 2009-09-15 Riken Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1744770A2 (en) 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
CA2582255A1 (en) 2004-08-30 2006-08-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) * 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
MX360062B (es) * 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
CN102993037B (zh) 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
EP2922576B1 (en) 2012-11-21 2017-11-08 Horizon Therapeutics, LLC Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
RU2755904C2 (ru) 2015-04-20 2021-09-22 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
US20200157033A1 (en) 2020-05-21
EP3621947A4 (en) 2021-03-10
EP3621947A1 (en) 2020-03-18
AU2018266357B2 (en) 2022-12-08
US11066352B2 (en) 2021-07-20
WO2018208677A1 (en) 2018-11-15
CA3063134A1 (en) 2018-11-15
IL270413B (en) 2022-08-01
AU2018266357A1 (en) 2019-11-14
CN110740988A (zh) 2020-01-31
JP2020519624A (ja) 2020-07-02
MX389665B (es) 2025-03-20
IL270413A (https=) 2020-01-30
JP7126520B2 (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
JP3261123B2 (ja) ラクタムフリーのアミノ酸
EP2573070B1 (en) Crystal form of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparation method and use thereof
JP6061081B2 (ja) 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iまたはii、それを含有する医薬品調製物、5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iの製造方法、および5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンナトリウム塩の結晶形iiの製造方法
KR101888215B1 (ko) L-오르니틴 페닐아세테이트의 제조 방법
EP3023410B1 (en) 5-BROMINE-2-(alpha-HYDROXYPENTYL)BENZOIC ACID SODIUM SALTS IN DIFFERENT CRYSTAL FORMS, AND PREPARATION METHOD THEREOF
JP2014144916A (ja) 2−アシルアミノチアゾール化合物の結晶
US10696629B2 (en) Crystalline form of dextral oxiracetam, preparation method therefor and use thereof
KR20200024145A (ko) L-오르니틴 페닐아세테이트의 제조방법
KR100979077B1 (ko) 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
CZ321095A3 (en) Heterocyclic compounds
US9751840B2 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20170071431A (ko) 오로트산 l-카르니틴의 결정질 다형체, 이의 제조방법 또는 용도
EP2647618A1 (en) Novel polymorphs and salts
EP1073625B1 (en) Tilidine mesylate, processes for its preparation and pharmaceutical composition thereof
JPS5857431B2 (ja) 脳血管拡張剤2,3−置換−4−複素環状アミノスルホニルベンゼンスルホンアミドの製法
KR100632470B1 (ko) 결정성 시부트라민 캄실레이트염과 이의 제조방법
JPH0217554B2 (https=)
JP2019043884A (ja) 敗血症治療剤
JPH02157276A (ja) 新規(‐)2‐ピラゾリン化合物及びそれを有効成分とする脳血管障害治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210430

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230627

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230627

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I